Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2003-07-09 Regulatory Filings
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Letter to Shareholders 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to the Australian Stock Exchange announcing that a letter has been sent to shareholders regarding a retraction from a professional body. It references a letter available on the company's website but does not contain any financial data, report content, or detailed disclosures. The length is only 602 characters, indicating it is a brief announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2003-07-09 English
Collaborative Program To Identify Genetic Markers 1
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 26 June 2003 from Genetic Technologies Limited to the Australian Stock Exchange. It announces a collaborative research program related to genetic markers for strawberries, including financial details of the program (A$2.1m) and the nature of the collaboration. There is no financial report, no regulatory filing, no voting results, no management changes, no earnings data, or any other formal report content. The document is an announcement of a business collaboration and research program, not a financial or regulatory report. Given the short length (1340 characters) and the nature of the content, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2003-06-25 English
Grants License to Inguran of Navasota Texas USA 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a short announcement dated June 16, 2003, from Genetic Technologies Limited to the Australian Stock Exchange. It announces the granting of a license to Inguran for genetic testing patents. The content focuses on a licensing agreement and financial terms related to signing fees and royalties. There is no financial report, earnings data, or detailed financial statements. The document is brief (under 5,000 characters) and serves as a corporate announcement about a licensing deal, which is a capital/financing update type of information. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2003-06-15 English
Appendix 3B - Incentive Options to new staff 9 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of unlisted employee options, their terms, exercise prices, expiry dates, and the number of securities issued. It also includes information about the securities' ranking, issue price (noted as NIL), purpose of the issue (incentive options to new staff), and dates related to the securities. The document references ASX (Australian Securities Exchange) rules and is clearly an official announcement related to new securities issuance and quotation application. This matches the description of a Share Issue/Capital Change announcement rather than a full financial report or other categories. The document length is substantial (15,000 characters), and it contains detailed information about the securities issued, not just a brief notice or a report publication announcement. Therefore, the appropriate classification is 'SHA' (Share Issue/Capital Change).
2003-06-04 English
Cross-Licensing agreement with Orchid Biosciences 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated May 28, 2003, from Genetic Technologies Limited to the Australian Stock Exchange. It announces a cross-licensing agreement with Orchid Biosciences, detailing the terms of the agreement, intellectual property rights exchanged, and financial considerations. There is no indication that this is a financial report, earnings release, or regulatory filing. The content focuses on a business agreement related to intellectual property and licensing, which is a capital or financing update. The document length is 3130 characters, which is relatively short but contains substantive information about a financing-related agreement rather than just an announcement of a report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2003-05-27 English
Appendix 3B - Exercise of Unlisted Vendor Options 9 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to the new issue of securities, application for quotation of additional securities, and agreement with the ASX (Australian Securities Exchange). It details the class and number of securities issued, exercise of options, issue price, purpose of the issue, and other related information. This type of document is a regulatory announcement specifically about capital raising or securities issuance and quotation. It is not a full financial report, earnings release, or management discussion. It fits the category of Capital/Financing Update (CAP) as it provides detailed information on new securities issued and their quotation on the exchange.
2003-05-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.